Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6EIG7
UPID:
CLC6A_HUMAN
Alternative names:
C-type lectin superfamily member 10; Dendritic cell-associated C-type lectin 2
Alternative UPACC:
Q6EIG7; A2RUK3
Background:
C-type lectin domain family 6 member A, also known as C-type lectin superfamily member 10 or Dendritic cell-associated C-type lectin 2, is a calcium-dependent lectin that serves as a pattern recognition receptor in the innate immune system. It binds alpha-mannans on C.albicans hypheas, triggering a cascade of immune responses including the activation of SYK, CARD9, and NF-kappa-B, which drives the maturation of antigen-presenting cells and shapes antigen-specific T-cell priming.
Therapeutic significance:
Understanding the role of C-type lectin domain family 6 member A could open doors to potential therapeutic strategies.